Legal Representation
Attorney
David A. Jackson
USPTO Deadlines
Application History
33 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 19, 2017 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jun 19, 2017 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Nov 23, 2016 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Oct 4, 2016 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 30, 2016 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Sep 30, 2016 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Sep 30, 2016 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 17, 2016 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 22, 2016 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 22, 2016 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 2, 2016 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 17, 2016 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Feb 8, 2016 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 2, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 2, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 2, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 16, 2015 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 16, 2015 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Sep 16, 2015 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 3, 2015 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN | Loading... |
| Jul 28, 2015 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
| Jul 14, 2015 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Jul 8, 2015 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jun 23, 2015 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 17, 2015 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 16, 2015 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 16, 2015 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 16, 2014 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 16, 2014 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 16, 2014 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 8, 2014 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 5, 2014 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 26, 2014 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
CHEMICAL REAGENTS AND BIOMOLECULES, IN PARTICULAR BIOLOGICAL MACROMOLECULES FOR INDUSTRY AND SCIENCE, REAGENTS FOR RESEARCH PURPOSES, ALL OF THE FOREGOING BEING GOODS WHICH TARGET OR WORK WITH RNA
First Use Anywhere:
0
First Use in Commerce:
0
Class 005
CHEMICAL PREPARATIONS FOR PHARMACEUTICAL OR MEDICAL PURPOSES, NAMELY, FOR THE TREATMENT OF NEUROLOGICAL, NEUROMUSCULAR, NEURODEGENERATIVE AND CARDIOVASCULAR DISEASES, FOR THE TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES AND TUMOURS, FOR TREATMENT OF METABOLIC DISEASES AND FOR TREATMENT OF HERITABLE GENETIC DISEASES OR FOR THERAPIES REPLACING PROTEINS OR ENZYMES; PHARMACEUTICAL AND VETERNARY MEDICAL PREPARATIONS FOR THE TREATMENT OF NEUROLOGICAL, NEUROMUSCULAR, NEURODEGENERATIVE AND CARDIOVASCULAR DISEASES, FOR THE TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES AND TUMOURS, FOR TREATMENT OF METABOLIC DISEASES AND FOR TREATMENT OF HERITABLE GENETIC DISEASES OR FOR THERAPIES REPLACING PROTEINS OR ENZYMES; IMMUNOSTIMULATORY COMPOSITIONS; VACCINES, ADJUVANT IMMUNOSTIMULANTS; PHARMACEUTICALS AND MEDICAMENTS BASED ON/CONTAINING/PREPARED FROM BIOLOGICAL MACROMOLECULES FOR THE TREATMENT OF NEUROLOGICAL, NEUROMUSCULAR, NEURODEGENERATIVE AND CARDIOVASCULAR DISEASES, FOR THE TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES AND TUMOURS, FOR TREATMENT OF METABOLIC DISEASES AND FOR TREATMENT OF HERITABLE GENETIC DISEASES OR FOR THERAPIES REPLACING PROTEINS OR ENZYMES; GENE THERAPY PRODUCTS, NAMELY, NUCLEIC ACID MACROMOLECULES FOR IN VIVO EXPRESSION; FOOD SUPPLEMENTS FOR MEDICAL USE, ALL OF THE FOREGOING BEING GOODS WHICH TARGET OR WORK WITH RNA
First Use Anywhere:
0
First Use in Commerce:
0
Class 044
MEDICAL AND VETERINARY SERVICES, IN PARTICULAR FOR THERAPEUTIC AND PROPHYLACTIC TREATMENT OF TUMOR DISEASES, INFECTIOUS DISEASES, AUTOIMMUNE DISEASES AND ALLERGIES, FOR THE TREATMENT OF HEREDITARY DISORDERS AND FOR PROTEIN OR ENZYME SUPPLEMENT THERAPY, FOR THE TREATMENT OF NEUROLOGICAL, NEUROMUSCULAR, NEURODEGENERATIVE AND CARDIOVASCULAR DISORDERS AND FOR THE TREATMENT OF ENDOCRINOLOGICAL DISORDERS
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
001
005
044